New AZ chief gets $6.4M to make up for Roche forfeit

AstraZeneca ($AZN) didn't send flowers to Pascal Soriot to woo him away from Roche ($RHHBY). No, its new chief executive got something much more valuable in the bargain: A £4 million ($ 6.44 million) payment. It's not exactly a signing bonus, though. The $6.44 million compensates Soriot for his loss of long-term incentive compensation from Roche. Story

Suggested Articles

Joe Jimenez has (another) new gig. The ex-Novartis boss joined the board of Century Therapeutics, a startup working on off-the-shelf cell therapies.

As Pfizer posts its full-year financials today, as usual it’s also sneaked in several dropped projects from its pipeline.

The short seller thinks Principia’s approach to the treatment of autoimmune diseases is “misguided” and likely to lead to clinical failures.